skip to main content

Comment on: Rowan et al. Metformin in Gestational diabetes: The Offspring Follow-Up (MiG TOFU): body composition at 2 years of age. Diabetes Care 2011;34:2279-2284

Barbour, Linda A ; Van Pelt, Rachael E ; Brumbaugh, David E ; Hernandez, Teri L ; Friedman, Jacob E

Diabetes care, March 2012, Vol.35(3), pp.e28; author reply e30 [Peer Reviewed Journal]

Full text available

Citations Cited by
  • Title:
    Comment on: Rowan et al. Metformin in Gestational diabetes: The Offspring Follow-Up (MiG TOFU): body composition at 2 years of age. Diabetes Care 2011;34:2279-2284
  • Author: Barbour, Linda A ; Van Pelt, Rachael E ; Brumbaugh, David E ; Hernandez, Teri L ; Friedman, Jacob E
  • Subjects: Body Composition -- Physiology ; Diabetes, Gestational -- Drug Therapy ; Metformin -- Therapeutic Use
  • Is Part Of: Diabetes care, March 2012, Vol.35(3), pp.e28; author reply e30
  • Description: We applaud Dr. Rowan and the MiG TOFU (Metformin in Gestational diabetes: The Offspring Follow-Up) investigators for their intense efforts at following the 2-year offspring outcomes from the MiG trial (1). Understanding how in utero exposures impact longer-term offspring consequences is critical. However, we feel compelled to caution against overinterpretation of this study's findings. Of note, 46% of the mothers in the metformin group required insulin to achieve adequate glycemic control (1); therefore, ∼50% in this group actually received both. Although 43% of the total infant cohort received anthropometric measures at 2 years, only ∼15% received dual-energy X-ray absorptiometry (DEXA) scans, thus potentially biasing the results. The absence of any differences in the …
  • Language: English
  • Identifier: E-ISSN: 1935-5548 ; PMID: 22355031 Version:1 ; DOI: 10.2337/dc11-2107

Searching Remote Databases, Please Wait